PCN172

TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A TAXANE: A RETROSPECTIVE LONGITUDINAL STUDY

Cohan C1, Stroak A1, O’Laury BA1, Roth A1, Cook GA1

1Covance Pty Ltd, Sydney, Australia, 2Bristol-Myers Squibb Pharmaceuticals, Melbourne, Australia

OBJECTIVES: Current treatment practice for patients in Australia with advanced breast cancer (ABC) who have previously been treated with an anthracycline and a taxane (A&CT) are not well defined. There is no “gold standard” treatment for these heavily pre-treated patients. A retrospective longitudinal survey was conducted to gain an insight into the treatments currently used in this patient group. METHODS: Four public hospitals provided patient level data. Inclusion criterion: ABC women ≥18 years with ABC who had previously received A&CT therapy and had ≥3 months follow-up. Information on demographics, disease characteristics and treatment history was obtained from medical records of all eligible patients. Descriptive statistics were performed by disease characteristics and treatments prescribed by line of therapy post A&CT. RESULTS: Data were obtained from 79 patient records. The mean (SD) age at initial diagnosis was 51.5 (10.9) years with most patients having stage IIIA disease (45.6%). Seventy four percent (93.7%) had previously undergone surgery. The most commonly first-line therapies post A&CT were monotherapy or combination use of radiotherapy (39/79, 49.4%), cytotoxic chemotherapy (36/79, 45.6%), targeted therapy (11/79, 13.9%) and hormonal therapy (8/79, 10.3%). Paclitaxel, whether used alone or in combination, was the most common first-line cytotoxic treatment post A&CT (11/79, 13.9%), followed by cyclophosphamide (10/79, 12.7%), doxorubicin (9/79, 11.4%) and docetaxel (7/79, 8.9%). Cytotoxic mono-chemotherapies were more commonly prescribed first-line post A&CT than cytotoxic combination treatments (31.6% vs. 13.9%) with paclitaxel (9/79, 11.4%), docetaxel (3/79, 6.3%) and capecitabine (4/79, 5.1%) being most frequently prescribed. FEC (4/79, 5.1%) and doxorubicin/cyclophosphamide (3/79, 3.8%) were the most commonly administered cytotoxic first-line combinations. CONCLUSIONS: The considerable variation in the treatments prescribed for patients with ABC who have previously received A&CT highlights the need for effective treatment options. Radiotherapy and cytotoxic chemotherapy were the most frequently administered therapies, with paclitaxel being most commonly prescribed cytotoxic agent.

INDIVIDUAL’S HEALTH – Clinical Outcomes Studies

PIH1

PERCEPTION OF PAIN AFTER CAESAREAN SECTION FROM THE POINT OF VIEW OF PUERPERAL MOTHERS

Kovács E1, Vráncs I1, Boncz I1, Pajantse A1, Bodis J1, Gabara K1, Kristófér J1

1University of Pécs, Pécs, Hungary

OBJECTIVES: Pain, such as pain following Caesarean section is a subjective and complex experience, from the intensity of which we can get a forecast with the respect of a number of influencing factors. The aim of this study is to examine those factors that influence postoperative pain after Caesarean section. METHODS: Our examination was made among women and went through a Caesarean section University of Pécs Obstetric and Gynecology Clinic and Hospital of Baranya County between October 1, 2008 and December 31, 2008 in Hungary. Our own questionnaire and a numerical classifier scale were used to measure the intensity of pain. Under the examination time we got back altogether 183 valuable questionnaires from the twoWide variations in pain perception even in primiparous patients were identified. There were ten first-line, ten second-line and twelve third-line chemotherapy regimens reported, reflecting variation in practice. However, dominant treatment pathways emerged for each stage of treatment, with: first-line treatment with oxaliplatin-based regimens, second-line treatment with irinotecan-based regimens, and third-line treatment with mitomycin-based regimens. Experts estimated the frequency of: febrile neutropenia 8.4% (95% CI: 6.7–10.0), septic neutropenia 4.7% (95% CI: 3.4–6.0), and severe diarrhoea 13.1% (95% CI: 10.8–15.5). CONCLUSIONS: This study captured the heterogeneity in chemotherapy prescribing practice and patient management within CRC specialties and obtained necessary data to inform the appropriate model structure for base case and subsequent structural and parameter sensitivity analyses.

PIH2

ADVERSE EVENTS ASSOCIATED WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI’S) ANTIDEPRESSANT MEDICATIONS AMONG CHILDREN: A REVIEW OF THE FDA ADVERSE EVENT REPORTING SYSTEM (AERS)

Chen H

University of Houston, Houston, TX, USA

OBJECTIVES: To examine the adverse events in children treated with SSRIs reported through treatment with irritant event Reporting System in response to the increased risks of suicide among children being treated with antidepressants. METHODS: A retrospective pharmacovigilance analysis was conducted using the January 2004 to September 2006 FDA Adverse Event Reporting System (AERS) data. The adverse drug reactions (ADRs) associated with SSRIs antidepressants were studied to examine their role in the incidence of the ADEs as the Primary and Secondary suspect. Children were defined as patients below 18 years. RESULTS: Out of 68,936 ADE cases involving SSRIs antidepressants, the SSRIs were identified as the primary suspect in 27,075 cases and as the secondary suspect in 6,713 cases. Of those cases, there were merely 1,780 (5.2%) cases involving children. The number of cases reported to the FDA per quarter was 161.81 on an average for the 11 quarters data. Paroxetine accounted for the majority of the reported ADE, 778 (43.70%) cases involving children followed by Sertraline 315 (17.69%) and Escitalopram 273 (15.33%). Despite the low reporting rate, adverse events associated with SSRIs antidepressants can have serious consequences. Suicide attempt was reported in 579 cases (16.88%) followed by psychotic disorders in 420 cases (12.24%). More than one third (608, 38.23%) of those cases led to hospitalization. CONCLUSIONS: Despite the adverse events reported for SSRIs antidepressants being taken by children were low; the consequences of those adverse events can be very serious. Suicide attempt was the most commonly reported adverse event. Paroxetine was the most common SSRi to be reported for adverse events and the main outcome was hospitalization.

PIH3

DUTASTERIDE PLUS TAMSULOSIN PROVIDES SUPERIOR IMPROVEMENT IN PATIENT-REPORTED OUTCOMES: 4-YEAR RESULTS FROM THE COMBINATION OF AVOIDAT® AND TAMSULOSIN (COMBAT) STUDY

Haillot O1, Budia A2, Wilson T3, Black I3

1University of Rennes, Tours, France, 2M2C, Fe University Hospital, Valencia, Spain, 3GlaxoSmithKline, Research Triangle Park, NC, USA

OBJECTIVES: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) represent a significant burden in affected men, with increasingly older LUTS associated with a lower quality of life (QoL). The CombAT study (n = 4844) showed that dutasteride plus tamsulosin provided significantly greater symptom and QoL improvement versus either monotherapy. Here we present 4-year data on the effects of dutasteride plus tamsulosin compared with monotherapy on the patient-reported health outcomes, BPH Impact Index (BII) and International Prostate Symptom Score (IPSS) Q8. METHODS: Following screening, eligible subjects entered a single-blind run-in period during which they received dutasteride and tamsulosin placebos for four weeks. All subjects were then randomised to receive 0.5 mg dutasteride, 0.4 mg tamsulosin or the combination once daily for 4 years. The primary endpoint for the 4-year analysis was time to acute urinary retention or BPH-related surgery; secondary endpoints included change from baseline in IPSS, BII and IPSS Q8. RESULTS: At baseline, mean BII and IPSS Q8 were 5.3 and 3.6, respectively, in all three treatment groups. Mean change from baseline in BII at Month 48 was -2.2 with combination therapy, -1.8 with dutasteride and +1.0 with tamsulosin (both p < 0.001 versus combination). For IPSS Q8, the corresponding values were -1.5 with combination, -1.3 with dutasteride and -1.1 with tamsulosin (both p < 0.001 versus combination). Improvement in BII and IPSS Q8 from baseline with combination therapy was statistically greater than with dutasteride from 3 months; compared with tamsulosin, the improvement from baseline with combination was statistically greater from 9 months (BII) and 12 months (IPSS Q8). CONCLUSIONS: Dutasteride combined with tamsulosin delivers superior improvement in health outcomes (BII and IPSS Q8) versus either monotherapy. The superiority of combination therapy over dutasteride was observed from three months, and over tamsulosin as early as nine months.

PIH4

ROLE OF LIFESTYLE-RELATED FACTORS IN PELVIC FLOOR MUSCLE STRENGTH CHANGES DURING PREGNANCY

Hock M1, Krása J1, Kristófér J1, Boncz I1, Bodis J1

1University of Pécs, Pécs, Hungary

OBJECTIVES: To assess strength and duration of pelvic floor muscle (PFM) contraction and to monitor the changes of lifestyle-related factors (body weight, constipation, vaginal wall laxity and physical activity) during pregnancy. METHODS: Our study recruited pregnant women during the 2nd and 3rd trimester of their pregnancy. All subjects were then randomised into three groups: PFM training (low, moderate, high intensity training) and the control group (no training). PFM strength was assessed every 4 weeks using a manual testing device for measuring vaginal pressure. Statistical data were calculated according to mean, standard deviation, T-test methods and the results were considered to be reliable when p ≤ 0.05. RESULTS: Data of 93 women were analyzed. The maximum PFM strength of nulliparous women (n = 36) was significantly higher (p = 0.003) than that of pregnant women (n = 57). The duration of maximum contraction in case of pregnant women proved to be markedly longer (p = 0.011) than during pregnancy. Regarding lifestyle factors even when BMI and constipation were involved no